Joan H. Schiller, MD

Logistical hassles hinder lifesaving lung cancer screenings

Publish date: March 21, 2023

Scheduling lung cancer scans can be very difficult because of unwieldy internal processes.

Publish date: January 26, 2023

The patient’s voice has great value in the clinic and in research. Here are a few examples.

Publish date: January 26, 2023

Findings from the 2022 Lancet Countdown on health and climate change have been issued.

Publish date: December 7, 2022

Talking to a patient with lung cancer can be like navigating a minefield of language pitfalls regardless of whether they are smokers.

Publish date: October 4, 2022

FDA’s approval of trastuzumab deruxtecan is a game-changer for NSCLC patients with HER alterations.

Publish date: September 30, 2022

Many years after their discovery, we finally have a new string of EGFR-TKI approvals for NSCLC.

Publish date: July 12, 2022

Targeted therapies are the ideal in drug development. New drugs that target KRAS (G12C) mutations mark a significant leap forward in oncology.

Publish date: June 27, 2022

Phase 3 trials are needed to determine whether neoadjuvant chemo/immunotherapy outperforms adjuvant chemo/immunotherapy.

Publish date: May 26, 2022

The increase in the Earth’s temperature causes extreme weather events which will inevitably impact our patients.